Low-dose and high-dose methotrexate are two different drugs in practical terms

International Journal of Rheumatic Diseases

Volumn 13, Issue 4, 2010, Pages 288-293

  Malaviya, Anand N ^a   Sharma, Amit ^a   Agarwal, Divya ^a   Kapoor, Sanjiv ^a   Garg, Shriram ^a   Sawhney, Sujata ^a  

^a ISIC Superspeciality Hospital   (India)

Author keywords

High dose methotrexate; Low dose methotrexate; Methotrexate; Oncology; Rheumatology

Indexed keywords

ACETYLSALICYLIC ACID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLINIC ACID; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOTRIENE B4; LIPOXYGENASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; METHOTREXATE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; RHEUMATOID FACTOR; THROMBOXANE B2;

ALOPECIA; ARTICLE; BONE MARROW TOXICITY; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG URINE LEVEL; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HEART DISEASE; HERPES ZOSTER; HUMAN; INFECTION; LEUKEMIA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG TOXICITY; LYMPHOMA; MUCOSA INFLAMMATION; NEOPLASM; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN SECRETION; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; ANTIRHEUMATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METHOTREXATE; RHEUMATIC DISEASES; RISK ASSESSMENT; TERMINOLOGY AS TOPIC; TREATMENT OUTCOME;

EID: 77958088656     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2010.01564.x     Document Type: Article

References (47)

1. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolf JA (1948) Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroylglutamic acid (aminopterin). N Engl J Med 238, 787-93.
2. Devita VT, Lawrence TS, Rosenberg SA, DePinto RA, Weinberg RA (2008) Pharmacology of cancer chemotherapy: antimetabolite - methotrexate. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Principles and Practice of Oncology, 8th edn, pp 427-28. Lippincott Williams & Wilkins, Philadeplhia.
3. Ackland SP, Schilsky RL (1987) High- dose methotrexate: a critical reappraisal. J Clin Oncol 5, 2017-31.
4. Treon SP, Chabner BA (1996) Concepts in use of high-dose methotrexate therapy. Clin Chem 42, 1322-9.
5. Gubner R, August S, Ginsberg V (1951) Therapeutic suppression of tissue reactivity. Effect of aminopterin in Rheumatoid Arthritis and psoriasis. Am J Med Sci 221, 176-82.
6. Malaviya AN, Many A, Schwartz RS (1968) Treatment of dermatomyositis with methotrexate. Lancet 2, 485-8.
7. Hoffmeister RT (1983) Methotrexate in rheumatoid arthritis: 15 years experience. Am J Med 75(6A), 69-73.
8. Hoffmeister RT (1972) Methotrexate in rheumatoid arthritis. Arthritis Rheum 15, 114.
9. Weinblatt ME, Coblyn JS, Fox DA, et al. (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312, 818-22.
10. Andersen PA, West SG, O'Dell JR, Via CS, Claypool RG, Kotzin BL (1985) Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 103, 489-96.
11. Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I (1989) Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 16, 313-20.
12. Schnabel A, Reinhold-Keller E, Willmann V, Gross WL (1994) Tolerability of methotrexate starting with 15 or 25 mg/week for rheumatoid arthritis. Rheumatol Int 14, 33-8.
13. Verstappen SM, Jacobs JW, Van Der Veen MJ, et al. (2007) Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66, 1443-9.
14. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J (2009) Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 68, 1086-93.
15. Braun J, Rau R (2009) An update on methotrexate. Curr Opin Rheumatol 21, 216-23.
16. Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS (2003) Methotrexate as the 'anchor drug' for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 21, S179-85.
17. Visser K, Van Der HD (2009) Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 68, 1094-9.
18. Treon SP, Chabner BA (1996) Concepts in use of high-dose methotrexate therapy. Clin Chem 42 8 (B), 1322-9.
19. Von Hoff DD, Penta IS, Helman U, Slavik M (1977) Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep 61, 745-8.
20. Zhu J-J, Gerstner ER, Engler DA, et al. (2009) High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol 11, 211-5.
21. Woods RL, Fox RM, Tattersall MHN (1981) Methotrexate treatment of squamous-cell head and neck cancers: dose-response evaluation. Br Med J 282, 600-2.
22. Nesbit M, Krivit W, Heyn R, Sharp H (2006) Acute and chronic effects of methotrexate on hepatic, pulmonary, and skeletal systems. Cancer 37(Suppl 2), 1048-54.
23. Hersh EM, Wong VG, Henderson ES, Freireich EJ (2006) Hepatotoxic effects of methotrexate. Cancer 19, 600-6.
24. Macdonald J (1998) Cancer chemotherapy and the liver. Clin Liver Dis 2, 631-42.
25. Jaffe N (2006) Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 30, 1627-31.
26. Ali A, Schmidt MF (2008) Drug-induced pulmonary toxicity eMedicine specialties > Pulmonology > iatrogenic pulmonary disorders updated September 24, (accessed 12 May 2010).
27. Salliot C, Van Der Heijde D (2009) Long term safety of methotrexate monotherapy in rheumatoid arthritis patients: a systematic literature research. Ann Rheum Dis 68, 1100-4.
28. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F (2002) Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359, 1173-7.
29. Van HalmVP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE (2006) Disease modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 8, R151.
30. Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C (2000) Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease modifying anti-rheumatic drugs. Rheumatology (Oxford) 39, 975-81.
31. Visser K, Van Der Heijde DM (2009) Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol 27, 1017-25.
32. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE (2002) Predictors of infection in rheumatoid arthritis. Arthritis Rheum 46, 2294-300.
33. Wolfe F, Michaud K, Chakravarty EF (2006) Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 45, 1370-5.
34. McLean-Tooke A, Aldridge C, Waugh S, Spickett GP, Kay L (2009) Methotrexate, rheumatoid arthritis and infection risk-what is the evidence? Rheumatology (Oxford) 48, 867-71.
35. Wolfe F, Michaud K (2004) Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50, 1740-51.
36. Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J (2002) Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 99, 3909-15.
37. Stamp LK, O'Donnell JL, Chapman PT, et al. (2009) Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis Rheum 60, 2248-56.
38. Bleyer WA (1978) The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 41, 36-51.
39. Cronstein BN (2005) Low-Dose Methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 57, 163-72.
40. Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J (1996) Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 30, 194-210.
41. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H (2005) The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 114, 154-63.
42. Reiss AB, Carsons SE, Anwar K, et al. (2008) Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum 58, 3675-83.
43. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52, 722-32.
44. Dursunoglu D, Evrengul H, Polat B, Tanriverdi H, Cobankara V, Kilic AKM (2005) Lp (a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 25, 241-5.
45. Weinblatt ME (1995) Efficacy of methotrexate in rheumatoid arthritis. Brit J Rheumatol 34(Suppl 2), 43-8.
46. Patrono C, Coller B, Dalen JE, et al. (2001) Platelet-Active drugs the relationship among dose, effectiveness and side effects. Chest 119, 39S-63S.
47. Weksler BB, Pett SB, Alonso D, Richter RC (1983) Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 308, 800-5.